Insulin treatment of type 2 diabetes: Considerations when converting from human insulin to insulin analogs

References

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 22 March 2011).
   Google Scholar
• Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29:2114–6.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596–615.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1–68.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(suppl 1):S11–63.
   Web of Science ®Google Scholar
• Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:511–27.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187–218.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–12.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–59.
   PubMed Web of Science ®Google Scholar
• Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins C Jr, Cook CB, . Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31: 564–71.
   PubMed Web of Science ®Google Scholar
• DeSouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26: 1485–9.
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33:1389–94.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, . Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119: 351–7.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, . Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983–90.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, . Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28.
   PubMed Web of Science ®Google Scholar
• Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther. 2011;13(suppl 1):S65–74.
   Google Scholar
• Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004;26:445–61.
   Google Scholar
• Polonsky KS, Given BD, van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81:442–8.
   PubMed Web of Science ®Google Scholar
• NovoLog® (insulin aspart [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; July 2011.
   Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med. 2005;352: 174–83.
   PubMed Web of Science ®Google Scholar
• Apidra® (insulin glulisine [rDNA origin] injection) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; February 2009.
   Google Scholar
• Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Med Gen Med. 2007;9:12.
   PubMedGoogle Scholar
• Humalog® (insulin lispro [rDNA origin] injection) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 18 May 2011.
   Google Scholar
• Humulin® R (regular insulin human injection [rDNA origin]) 100 units per mL (U-100) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 25 March 2011.
   Google Scholar
• Novolin® R (regular human insulin [rDNA origin]) [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; 14 May 2010.
   Google Scholar
• Humulin® N (NPH human insulin [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2 September 2009.
   Google Scholar
• Novolin® N (NPH human insulin [rDNA origin]) [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; 14 May 2010.
   Google Scholar
• Levemir® (insulin detemir [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk, Inc.; January 2012.
   Google Scholar
• Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, . A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–12.
   PubMed Web of Science ®Google Scholar
• Lantus® (insulin glargine [rDNA origin] injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US, LLC. April 2010.
   Google Scholar
• Cupp M. Comparison of insulins and injectable diabetes meds. Pharmacist's Letter/Prescriber's Letter. 2010;26:260304.
   Google Scholar
• Pearson TL. Practical aspects of insulin pen devices. J Diabetes Sci Technol. 2010;4:522–31.
   PubMedGoogle Scholar
• DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–64.
   PubMed Web of Science ®Google Scholar
• Hall DL, Drab SR, Havrilla PL. Advances in diabetes therapy: rapid- and long-acting insulin analogs. Drug Topics. 2006;150:e1–15.
   Google Scholar
• Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64:1415–34.
   PubMed Web of Science ®Google Scholar
• Hompesch M, Troupin B, Heise T, Elbroend B, Endahl L, Haahr H, . Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006;8:568–73.
   PubMed Web of Science ®Google Scholar
• Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290–9.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356: 443–5.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Liebl A, Abrahamson MJ. Insulin detemir: a historical perspective on a modern basal insulin analogue. Prim Care Diabetes. 2010;4(suppl 1):S31–42.
   Google Scholar
• Porcellati F, Rossetti P, Ricci BN, Marzotti S, Lucidi P, Luzio S, . Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care. 2007; 30:2447–51.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51: 408–16.
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, . A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176–8.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542–8.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr TA, . Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin. 2010;26:1621–8.
   PubMed Web of Science ®Google Scholar
• Morales J. Defining the role of insulin detemir in basal insulin therapy. Drugs. 2007;67:2557–84.
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, . Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269–74.
   PubMed Web of Science ®Google Scholar
• Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest. 2007;27:279–85.
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418–27.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab. 2007;9:902–13.
   PubMed Web of Science ®Google Scholar
• Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738–44.
   PubMed Web of Science ®Google Scholar
• Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952–9.
   PubMed Web of Science ®Google Scholar
• Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, . Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41–6.
   PubMed Web of Science ®Google Scholar
• Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, . Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501–6.
   PubMed Web of Science ®Google Scholar
• Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396–402.
   PubMed Web of Science ®Google Scholar
• Sreenan S, Virkamaki A, Zhang K, Hansen JB. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract. 2008;62:1971–80.
   Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–81.
   PubMed Web of Science ®Google Scholar
• Diabetes Education Online. Calculating insulin dose. Available at: http://dtc.ucsf.edu/types-of-diabetes/type2/treatment-of-type-2-diabetes/medications-and-therapies/type-2-insulin- rx/calculating-insulin-dose/ (accessed 20 February 2012).
   Google Scholar
• Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28: 1282–8.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–51.
   PubMed Web of Science ®Google Scholar
• Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11:623–31.
   PubMed Web of Science ®Google Scholar
• McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy. 2010;30:1159–78.
   Google Scholar
• Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007;14:230–6.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program Expert Panel on Detection EAToHBCIA. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
   Web of Science ®Google Scholar
• Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901–7.
   PubMed Web of Science ®Google Scholar
• Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care. 2005;28:1588–93.
   PubMed Web of Science ®Google Scholar
• Opie LH, Yellon DM, Gersh BJ. Controversies in the cardiovascular management of type 2 diabetes. Heart. 2011;97: 6–14.
   Google Scholar
• Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, . Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:34i–43i.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129–39.
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, . New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268: 471–82. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes. 2005;23:78–86.
   Google Scholar
• Hirsch IB, Bergenstal RM, Parkin CG, . A real-world approach to insulin therapy in primary care practice. Clinical Diabetes. 2005;23:78–86.
   Google Scholar